Parker Waichman LLP

Novartis Settles Trileptal Marketing Allegations

Novartis AG, a Swiss pharmaceutical giant, announced that its offices in the United States have reached a plea agreement with federal investigators, reported the Wall Street Journal. Allegations include criminal charges concerning how Novartis marketed its epilepsy drug Trileptal, added the Journal. Novartis will pay a $185 million fine, according to the agreement. Both civil […]

Novartis AG, a Swiss pharmaceutical giant, announced that its offices in the United States have reached a plea agreement with federal investigators, reported the Wall Street Journal. Allegations include criminal charges concerning how Novartis marketed its epilepsy drug <"https://www.yourlawyer.com/topics/overview/trileptal">Trileptal, added the Journal. Novartis will pay a $185 million fine, according to the agreement.

Both civil and criminal investigations have been conducted over how Novartis promoted Trileptal and its marketing of the drug for uses not approved by the U.S. Food and Drug Administration (FDA), said the Journal. Such off-label marketing is illegal. “Payments made to health-care providers in connection with this medicine,” were also reviewed, Novartis said, quoted the Journal. Novartis previously revealed an investigation was underway, said the Journal, which noted that the probe is being conducted by the U.S. Attorney’s Office for the Eastern District of Pennsylvania.

The guilty plea and payment are meant to resolve criminal allegations of a violation of the U.S. Food, Drug and Cosmetic Act; the agreement is “contingent on court approval,” Novartis said, quoted the Journal.

The drug maker is also negotiating with the same investigators “to resolve civil claims relating to Trileptal,” it said, reported the Journal. Experts believe a settlement could be nearing and Novartis said it increased its financial reserves for Trileptal investigations by $318 million in 2009’s fourth quarter, for a total of $397 million; it is not known if this reserve amount includes the $185 million fine, noted the Journal.

Last year, we wrote that federal regulators approved new suicide warnings for more than two-dozen epilepsy drugs, including Novartis’ Trileptal. The FDA ordered the label update when it issued a public-health advisory regarding the association between epilepsy drugs and suicidal thoughts and behavior. The warnings resulted from the FDA’s review of 199 clinical trials of 11 antiepileptic drugs which showed patients receiving antiepileptic drugs had almost twice the risk of suicidal behavior or thoughts (0.43 percent) compared to patients receiving a placebo (0.24 percent).

Novartis also said the investigative team is looking into “potential off-label marketing,” quoted the Journal, as well as health care provider payments for five other Novartis drugs: Diovan, Exforge, Sandostatin, Tekturna, and Zelnorm.

“Novartis is unable to assess with reasonable certainty the outcome of the investigation related to these five products or the amounts, which could be material, that it might be required to pay to resolve this investigation,” it said in its statement, said the Journal.

The Journal pointed out that other drug companies, such as Pfizer Inc. and Eli Lilly & Co., have also agreed to large settlements with U.S. investigators regarding the pharmaceutical companies marketing practices. In September, AstraZeneca reached an early agreement to pay out $520 million to settle issues concerning how it marketed Seroquel, a drug prescribed for schizophrenia.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
I would like to thank Kathy and Alex for all their hard work and dedication through out the entire process. I am very happy with the outcome of the case. I would highly recommend to my family and friends.
Alanah Rotunno
7 months ago
5 Star Reviews 150
Great law firm, no complaints...If you want to win, look no further!
rolando velez
7 years ago
5 Star Reviews 150
Good lawyers, I would recommend to anyone in need of legal services.
Guy Bradley
7 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038